Journal of AOAC International - Estimation of pioglitazone hydrochloride and metformin hydrochloride in tablets by derivative spectrophotometry and liquid chromatographic methods
July 1, 2005 -- Two simple and accurate methods of analysis to determine pioglitazone hydrochloride (1310) and metformin hydrochloride (MET) in combined dosage forms...
Business Wire - IMPAX Receives Final FDA Approval for Metformin Hydrochloride Extended Release Tablets, 500mg; Ninth Approval in 2004
August 2, 2004 -- HAYWARD, Calif. -- IMPAX Laboratories, Inc. (NASDAQ:IPXL) announced that the U.S. Food and Drug Administration (FDA) has granted final marketing...
Drug Store News - Teva Pharmaceuticals - Reporter's Notebook: Generic News - introduces metformin hydrochloride tablets - Brief Article
May 19, 2003 -- Teva Pharmaceuticals earlier this month introduced its metformin hydrochloride tablets, 1,000 mg, the bioequivalent to Glucophage. In addition to...
Drug Store News - Andrx received tentative FDA approval to market metformin hydrochloride extended-release tablets - Generic News - generic diabetes drug - Brief Article -...
May 20, 2002 -- Andrx received tentative FDA approval to market metformin hydrochloride extended-release tablets, the generic version of Bristol-Myers Squibb's type...
Business Wire - Santarus Commences GLUMETZA Promotion
October 10, 2008 -- Marketing Campaign Focuses on Achieving Improved Glycemic Control in Type 2 Diabetes Patients SAN DIEGO -- Santarus, Inc. (NASDAQ:SNTS), a...
Business Wire - Depomed Reports Second Quarter 2008 Financial Results
July 31, 2008 -- MENLO PARK, Calif. -- Depomed, Inc. (NASDAQ:DEPO) today reported financial results for the second quarter ended June 30, 2008. Depomed reported net...
Business Wire - Depomed Achieves Tier 2 Reimbursement Status for Glumetza® With CVS Caremark
July 9, 2008 -- MENLO PARK, Calif. -- Depomed, Inc. (NASDAQ:DEPO) announced today that it has entered into a contract with CVS Caremark, the nation's largest...
Business Wire - Depomed Announces Allowance of Additional U.S. Patent Covering Gabapentin GR
June 17, 2008 -- Patent Coverage to be Extended to 2024 MENLO PARK, Calif. -- Depomed, Inc. (NASDAQ:DEPO) announced today that it has received a Notice of Allowance...
Business Wire - Depomed Secures $15 Million in Non-Dilutive Funding for Hot Flash Program
June 30, 2008 -- MENLO PARK, Calif. -- Depomed, Inc. (NASDAQ:DEPO) announced today that it has entered into an agreement with Oxford Finance Corporation and GE...
Business Wire - Depomed Settles Patent Litigation Against IVAX
April 7, 2008 -- Depomed to Receive $10 Million in Settlement and Royalties MENLO PARK, Calif. -- Depomed, Inc. (NASDAQ:DEPO) announced today that it has reached a...
